As butyrylcholinesterase (BChE) plays a role in the progression of symptoms and pathophysiology
of Alzheimer’s disease (AD), selective inhibition of BChE over acetylcholinesterase (…

… is the replacement of aromatic residues in the active site of AChE with aliphatic ones in BuChE,
which in turn leads to enzyme selectivity [… involved during Alzheimer disease progression …

… Selective BChE inhibition has been regarded as a viable therapeutic approach in Alzheimer’s
disease… As of now, a limited number of selective BChE inhibitors are available. To identify …

… considering structural differences in their peripheral site, exploiting a moiety replacement
approach based on the potent and selective hAChE drug donepezil. Hence, two small series of …

… activity of 0.012, fit value of 10.02 could be further subjected to drug development and
forwarded as better alternatives to the current batch of medicines used for the treatment of AD. …

… the late stage of Alzheimer’s disease (AD), development of selective BChE inhibitors is of
vital … Moreover, AChE knockout mice models indicated that BChE can potentially substitute for …

… In addition, Butyrylcholinesterase (BuChE) has also been … A similar but much smaller
difference in selectivity was … with cholinesterase inhibition, they may be an attractive alternative to …

… nomenclature, they can also be known by alternative names. AChE … Currently, extensive
research on Alzheimers disease is also … is an example of a selective inhibitor; in this case, it is a …

… butyrylcholinesterase (BChE) play important roles in human neurodegenerative disorders
such as Alzheimer’s disease… ) models, a practical and effective alternative to traditional wet lab …

… is modest and temporary.10 Therefore, development of novel therapeutic agents for Alzheimer's
disease is … previously used this fragment in the design of selective BuChE inhibitors.24 …